Stockscreener 앱 받기
36.55
1.29%
-0.63
전일 마감가:
$37.18
열려 있는:
$35.81
하루 거래량:
929.03K
Relative Volume:
1.08
시가총액:
$2.12B
수익:
$2.00B
순이익/손실:
$-119.19M
주가수익비율:
-16.69
EPS:
-2.19
순현금흐름:
$-61.88M
1주 성능:
-6.33%
1개월 성능:
-5.04%
6개월 성능:
-10.14%
1년 성능:
-39.16%
1일 변동 폭
$34.44
$36.84
1주일 범위
$34.44
$39.28
52주 변동 폭
$34.44
$62.79
Enovis Corp Stock (ENOV) Company Profile
명칭
Enovis Corp
전화
(302) 252-9160
주소
2711 CENTERVILLE ROAD, WILMINGTON
ENOV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENOV
Enovis Corp
|
36.51 | 2.12B | 2.00B | -119.19M | -61.88M | -2.19 |
|
ABT
Abbott Laboratories
|
131.48 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.05 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
376.19 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.56 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
71.69 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Enovis Corp Stock (ENOV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-10-03 | 개시 | JMP Securities | Mkt Outperform |
| 2024-06-13 | 개시 | JP Morgan | Neutral |
| 2024-02-13 | 개시 | Stephens | Overweight |
| 2024-01-22 | 개시 | UBS | Buy |
| 2024-01-03 | 개시 | William Blair | Outperform |
| 2023-12-15 | 재확인 | Needham | Buy |
| 2023-10-20 | 개시 | ROTH MKM | Buy |
| 2023-06-26 | 개시 | Needham | Buy |
| 2023-05-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-10-11 | 개시 | Goldman | Buy |
| 2022-09-12 | 개시 | Canaccord Genuity | Buy |
| 2022-09-12 | 개시 | Evercore ISI | Outperform |
| 2022-06-28 | 개시 | Argus | Hold |
| 2022-06-27 | 재개 | Loop Capital | Buy |
| 2022-06-16 | 개시 | Wells Fargo | Equal Weight |
모두보기
Enovis Corp 주식(ENOV)의 최신 뉴스
Enovis Corporation Reiterats Earnings Guidance for the First Quarter of 2025 - MarketScreener
Former LivaNova CEO to take corner office at Enovis - MassDevice
Enovis names McDonald as CEO - MSN
Enovis Names Damien McDonald as Chief Executive; Reaffirms Q1 Revenue Guidance - MarketScreener
Enovis names Damien McDonald as new CEO starting May 12 - Investing.com India
Enovis Appoints Damien McDonald as New CEO - TipRanks
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer - The Manila Times
Enovis Announces Appointment Of Damien Mcdonald As Chief Executive Officer - MarketScreener
Medical Device Expert Takes Helm at Enovis: Former LivaNova CEO to Drive Growth - Stock Titan
Enovis Corporation (NYSE:ENOV) Looks Inexpensive But Perhaps Not Attractive Enough - simplywall.st
Enovis Showcases Innovative Foot and Ankle Solutions at ACFAS Conference - MSN
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025 - GlobeNewswire
Enovis, Foundation Surgical and J&J MedTech Named Winners of OMTEC® Awards, Honoring Excellence in Orthopedic Innovation - Ortho Spine News
Revolutionary Bunion Surgery System Leads Enovis's Major Product Launch at ACFAS 2025 - Stock Titan
Enovis : trade; Publishes 2024 Corporate Social Responsibility Report -March 24, 2025 at 04:41 pm EDT - MarketScreener
Enovis Corp (ENOV) Stock Price Up 1.77% on Mar 19 - GuruFocus.com
Enovis Plans Leadership Change - The Healthcare Technology Report.
Enovis CEO Matthew Trerotola Announces Retirement Plan - TipRanks
Positive Outlook for Enovis: Strong Market Position and Strategic Growth Initiatives - TipRanks
Diabetic Footwear Market Demand : Identifying Key Growth Opportunities By 2032 | Enovis companies, Pilgrim - EIN News
Enovis Corporation Announces Participation in Upcoming Investor Conferences - MSN
Enovis Positioned for Growth: Buy Rating Highlights Strategic Execution and Undervaluation - TipRanks
Enovis to Participate in Upcoming Investor Conferences - The Manila Times
Enovis Leadership Reveals Investor Conference Schedule: Key Dates for Healthcare Investors - StockTitan
Enovis Hits Another 52-Week Low. Here’s Why It’s A Contrarian Buy. - Barchart
Enovis Hits Another 52-Week Low. Here’s Why It’s a Contrarian Buy. - TradingView
Enovis : rsquo; Louie Vogt on driving recon growth past $1B with M&A, knee breakthroughs, and foot and ankle expansion - Marketscreener.com
Enovis Corporation Reports Strong Growth Amid Challenges - MSN
William Blair Issues Optimistic Outlook for Enovis Earnings - MarketBeat
Enovis (NYSE:ENOV) Issues FY 2025 Earnings Guidance - MarketBeat
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates - MSN
Enovis Positioned for Growth: Buy Rating Backed by Strong Sales, Product Launches, and Attractive Valuation - TipRanks
Enovis (NYSE:ENOV) Reaches New 1-Year Low on Analyst Downgrade - MarketBeat
Enovis Reports Strong 2024 Sales Growth Despite Goodwill Impairment Charge - MSN
Needham & Company LLC Has Lowered Expectations for Enovis (NYSE:ENOV) Stock Price - MarketBeat
Enovis Continues To Languish Despite Decent Financial Results (NYSE:ENOV) - Seeking Alpha
Decoding Enovis Corp (ENOV): A Strategic SWOT Insight - GuruFocus.com
Diabetic Footwear Market Future Business Opportunities 2025-2032 | Enovis companies, Pilgrim Shoes, Drew Shoe - EIN News
Enovis (NYSE:ENOV) Issues Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Enovis Corporation (NYSE:ENOV) Q4 2024 Earnings Call Transcript - Insider Monkey
Enovis CEO Matt Trerotola Announces Retirement, Leadership Transition Underway - MSN
Rhumbline Advisers Acquires 1,938 Shares of Enovis Co. (NYSE:ENOV) - Defense World
Enovis Corp (ENOV) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Outlook - Yahoo Finance
Enovis’s Strong Financial Performance and Strategic Positioning Earns Buy Rating - TipRanks
Enovis Corporation Faces Financial Strain Amid U.S.-China Tariff Uncertainty - TipRanks
Enovis Corporation Reports Strong Sales Growth Amid Challenges - TipRanks
Enovis: Strong Financial Performance and Growth Potential Justify Buy Rating - TipRanks
Enovis Corp (ENOV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.69%
0.15%
자본화:
|
볼륨(24시간):